Techno Medica Co., Ltd.
6678・Standard Market・Electric Appliances
Business
Techno Medica Co., Ltd. is a medical device manufacturer established in 1987, whose core products are Blood Collection Tube Preparation Equipment & Systems that automate and streamline blood and urine sampling and testing operations. The company has a track record of installations at more than 2,500 medical facilities in Japan and more than 500 overseas, with its main customers being medical institutions such as hospitals and clinics. Its product lineup consists of three categories: Blood Collection Tube Preparation Equipment & Systems; Specimen Testing Equipment such as blood gas analyzers; and Consumables, etc. The company conducts R&D and design in-house while outsourcing manufacturing, adopting a fab-light business model. It is listed on the Standard Market of the Tokyo Stock Exchange.
Business Model
The structure involves building a customer base through initial sales of Blood Collection Tube Preparation Equipment & Systems and Specimen Testing Equipment, then capturing ongoing demand for consumables (labels, sensor cards, etc.) and maintenance services as the installed base of units grows. In FY2026 (ending March 2026), sales of Consumables, etc. amounted to ¥5,816 million, accounting for approximately 52% of total sales, functioning as a stable revenue source that complements fluctuations in equipment sales. Sales are conducted through two channels—direct sales and sales via distributors—and are deployed both domestically and overseas.
Company Strengths
The company was the world's first to develop blood collection tube preparation equipment, with a track record of installations at over 2,500 medical facilities domestically and over 500 overseas. In FY2026 (ending March 2026), sales of Blood Collection Tube Preparation Equipment & Systems grew substantially to ¥4,892 million (up 34.5% year on year), driven by successful solution proposals centered on the flagship model BC・ROBO-9000RFID.
The company has a revenue model in which demand for consumables structurally expands in line with the increase in the number of installed devices. In FY2026 (ending March 2026), sales of Consumables, etc. continued to grow steadily, reaching ¥5,816 million (up 3.0% year on year), accounting for approximately 52% of total sales. This mitigates the volatility risk of equipment sales and enhances the stability of earnings.
At the end of FY2026 (ending March 2026), the equity ratio stood at 80.2%, interest-bearing debt was zero, and cash and cash equivalents at period-end totaled ¥8,976 million. The company maintains financial soundness sufficient to fund R&D, capital expenditures, and shareholder returns (dividends of ¥471 million and share buybacks of ¥675 million) entirely from its own funds, giving it high resilience against fluctuations in the external environment.
ENVALITH's Perspective
Performance Trend
In FY2026 (ending March 2026), net sales were ¥11,237 million (up 13.4% year on year), operating profit was ¥1,668 million (up 28.3%), and ordinary profit was ¥1,717 million (up 31.8%), marking a clear recovery from the decline in FY2025 (ended March 2025). Domestic Blood Collection Tube Preparation Equipment & Systems drove the results, growing 37.3% year on year on steady progress in projects for large-scale facilities. A 1.5% year-on-year decrease in SG&A expenses, due to lower R&D spending, also contributed to the improvement in profit. However, the recording of a ¥192 million extraordinary loss for a provision for loss on discontinuation of manufacturing limited the growth in net income to 6.6%. The company's forecast for FY2027 (ending March 2027) calls for net sales of ¥10,300 million and operating profit of ¥1,100 million, anticipating a substantial decline in both revenue and profit, with the trend toward restrained investment by medical institutions and more selective capital spending expected to weigh on performance as an external factor. As shown by the trend over the past five fiscal years (operating profit of ¥1,862 million in FY2022 → ¥1,649 million in FY2023 → ¥1,840 million in FY2024 → ¥1,300 million in FY2025 → ¥1,668 million in FY2026), profit fluctuates significantly depending on the degree of concentration of large-scale orders received.
Growth Strategy
Aiming to achieve medium-term targets through deepening the domestic equipment and systems business, expanding overseas, and developing next-generation products
Strengthening proposals as a system solution that improves the efficiency of testing operations, centered on the BC・ROBO-9000RFID, the top-of-the-line model of Blood Collection Tube Preparation Equipment. In FY2026 (ending March 2026), domestic Blood Collection Tube Preparation Equipment & Systems sales reached ¥4,446 million (up 37.3% year on year), with orders from large-scale domestic facilities progressing smoothly.
Compact-type Blood Collection Tube Preparation Equipment increased sales in the Asian market, with overseas Blood Collection Tube Preparation Equipment & Systems sales for FY2026 (ending March 2026) reaching ¥446 million (up 11.8% year on year). However, the overseas sales ratio remained at 12.8%, down 1 point year on year, indicating that reducing dependence on the domestic market remains a work in progress.
A strategy of expanding the market's breadth by developing and selling Self-Monitoring Products (Healthcare Products) for general users, in addition to medical institutions. Sales expansion continues with a lineup of handheld and desktop Specimen Testing Equipment, but Specimen Testing Equipment sales in FY2026 (ending March 2026) fell to ¥528 million (down 15.1% year on year), affected by intensifying competition.
In FY2026 (ending March 2026), manufacturing of certain Blood Collection Tube Preparation Equipment models was discontinued from a sales strategy perspective, and a provision for loss on discontinuation of manufacturing of ¥192 million was recorded. The product line is being narrowed down to concentrate resources on highly profitable products and solutions. This is part of a structural reform aimed at strengthening medium- to long-term competitiveness.
Last updated: July 19, 2026